The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Chiasma disavows any obligation to update the information contained in such press releases after the date of their issuance.
|10/22/14||Chiasma Continues Development and Commercialization of Oral Octreotide|
|Jerusalem, Israel, October 22, 2014 - Chiasma recently announced its
plan to independently lead the development and commercialization of
Oral Octreotide (formerly Octreolin or OOA). Chiasma is an innovative
pharmaceutical company that uses its TPE system to switch injectable
drugs to oral delivery and identify new treatment options. Its work with
Oral Octreotide is aimed at providing patients with acromegaly an
alternative to the current treatment standard of lifelong injec... |
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent filings with the U.S. Securities and Exchange Commission.